According to Zhen, the trial comparing nivolumab (Opdivo) plus chemotherapy vs chemotherapy alone led to an overall survival (OS) benefit in patients with a PD-L1 combined positive score (CPS) of 5 or ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the FDA with priority review. The FDA accepted the biologics license ...

Different parts of Medicare can provide coverage for cancer treatments, including Opdivo. The coverage will depend on various factors, such as the phase of treatment and where a person receives ...

Department of Thoracic Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The second Affiliated Hospital of Nanchang Medical College, Nanchang, China ...